Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06015256
Other study ID # C21-75
Secondary ID 2022-A00651- 42
Status Recruiting
Phase N/A
First received
Last updated
Start date September 7, 2023
Est. completion date September 2030

Study information

Verified date January 2024
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact Pascal Chanez, PU-PH
Phone +334.91.96.58.64
Email pascal.chanez@univ-amu.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Asthma is a common chronic bronchial disease affecting 300 million people worldwide. The disease can be severe when it is not managed properly or when it is not controlled by treatments. Asthma is characterized by bronchial inflammation, bronchial hyperreactivity and tissue remodeling. Symptoms include episodes of coughing, dyspnoea and wheezing in relation with bronchial obstruction. The evolution is marked by the occurrence of exacerbations (increase of symptoms), most often triggered by viral infections, mostly due to rhinoviruses. The treatment of asthma is based on inhaled corticosteroid therapy sometimes combined with other treatments that help control the majority of asthma. However, about 10% of patients suffer from persistent symptoms despite these treatments. Natural killer (NK) cells are important actors of the antiviral innate immune response and are present in high numbers in the lungs. However, their role in severe asthma and its virus-induced exacerbations is unknown. The purpose of this work is to characterize NK cells in severe asthma in order to identify molecules expressed differently from control subjects. The goal is to assess whether these molecules could be potential biomarkers of a severe asthma subtype, also known as the endotype, and/or be the molecular control for exacerbation. The advantage of identifying biomarkers for inflammatory diseases lies in their usefulness in establishing a correct diagnosis, monitoring the progress of the disease and the effectiveness of treatments. The secondary objectives are to characterize the activation of NK cells in response to in vitro rhinovirus infection of different types, in monoculture or in a model of interaction with a bronchial epithelium, and identify one or more molecules involved in the interaction between bronchial epithelial cells and NK cells.


Recruitment information / eligibility

Status Recruiting
Enrollment 448
Est. completion date September 2030
Est. primary completion date September 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: - Consent form read, understood, approved and signed before any study procedure - Membership of a social security scheme or beneficiary of such a scheme - Patient aged over 18 Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation: - Diagnosis of severe asthma confirmed by a respirologist at an expert centre Case asthma controlled: - Asthma control confirmed by a lung specialist from an expert centre Case uncontrolled asthma excluding exacerbation: - Uncontrolled asthma confirmed by a lung specialist from an expert centre Case uncontrolled asthma with exacerbation: - Current exacerbation Exclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: - Person subject to a legal protection measure - Vulnerable population: minors, persons under guardianship or trusteeship or persons deprived of their rights to liberty by court order. - women with a known pregnancy - Inability or refusal to comply with research requirements - Active or weaned smoker > 15 PA - Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or opioids in the 10 days prior to inclusion Case patient with asthma: - Coexistence of a chronic inflammatory disease other than asthma Case healthy volunteers: - Coexistence of an inflammatory pathology Exclusion criteria: Cases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU/L (measured on the study sample)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
blood sample
Blood sample (56mL) taken in a heparin tube

Locations

Country Name City State
France Hôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du sommeil Marseille

Sponsors (1)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in expression of one or more molecules on the surface of NK cells Rationale for choice of primary endpoint: Our aim is to phenotype NK cells in different groups of severe asthma patients compared with control subjects, in order to identify at least one marker of disease discrimination on these cells. We are therefore looking for previously unknown changes in the expression of one or more molecules. day 1 to day 2555
Secondary Measurement of NK cell activation Change From Baseline in the expression of CD107, CD69 and interferon-?. day 1 to day 2555
Secondary Measurement of NK cell-induced epithelial cell activation and viability Change From Baseline in epithelial cell cohesion, mucin and cytokine (IL-8, type I interferon, IL-33 and TSLP) production day 1 to day 2555
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Completed NCT05318885 - The Effect of Nebulization Positions in Asthmatic Children N/A
Enrolling by invitation NCT06171932 - Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma
Not yet recruiting NCT06360185 - Retrospective Study of Patients With Acute Presentation for Asthma to an Emergency Department in UK (RAPAE)
Completed NCT03084016 - Asthma Breath Biomarker Assessment
Not yet recruiting NCT03296579 - Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma N/A
Completed NCT03154762 - Anti-inflammatory Effect of Nocturnal NIPPV on Acute Asthma N/A
Enrolling by invitation NCT04033666 - Analysis of Non-invasive Ventilatory Support Modes: High Flow Nasal Cannula and Non-invasive Ventilation N/A
Completed NCT03642418 - User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
Not yet recruiting NCT06377345 - Remote Patient Monitoring Solution for Chronic Respiratory Disease Management N/A